Your wafer allocation is confirmed, your packaging slot is booked, and the delivery date still slipped. In October 2026, the reason may sit at a step most procurement dashboards do not track: final test.
What Changed on October 8, 2026, and Why It Matters Immediately
The short answer: test capacity for AI-class silicon is now being sold forward, under contract, at a premium. According to TrendForce, reported on October 8, 2026, Taiwan-based OSAT provider Sigurd Microelectronics confirmed that its customers are signing testing capacity agreements lasting more than one year, a sign that test capacity is now being contracted well in advance of production.
The same report, relayed by Shanghai STAR Market Daily on October 7, 2026, states that certain memory-chip customers have agreed to pay higher prices to guarantee test slots, and that Sigurd has already initiated price increases. No verified percentage has been published for that increase, and any figure you hear beyond "price increase confirmed" should be treated as unverified.
Capacity is not waiting for buyers. Roughly 40% of Sigurd's capacity had been released by October 2026, and that released capacity was already secured by customers, according to the TrendForce account carried by Futunn (2026).
The device families named across the reporting are AI processors, ASICs, HPC chips and optical-communications chips, per Taiwan News (2026), with memory customers HBM4 Prices Up 121% in 2027: What OEM and EMS Buyers Must Plan For explicitly cited among those paying premiums.
Why does this matter today rather than next quarter? A wafer shortage hits before fabrication. A test bottleneck hits after it. Finished wafers can sit in a queue, fully fabricated and fully paid for, without becoming shippable components. This article separates what is confirmed from what is inferred, explains why test rather than wafer supply is now the binding constraint for some programs, and lists what a procurement team should verify before its next forecast cycle.
Why Is Testing Now a Bottleneck Separate From Wafer and CoWoS Supply?
Testing has become a forward-booked resource because the test steps for AI devices (high-performance wafer probing, burn-in, final test and product-specific qualification) require dedicated platforms that cannot be added as quickly as demand arrived. Attention in earlier shortage cycles focused on wafer fabrication and advanced packaging such as CoWoS; the Sigurd reporting shows that test capacity is now a constraint in its own right.
Sigurd's own capital allocation documents the shift. In May 2026, the company raised its 2026 capital-expenditure budget from NT$5.9 billion to NT$8.8 billion, with the increase directed at testing equipment for AI, ASIC, HPC and optical-communications chips, according to Taiwan News (2026). Three months earlier, in February 2026, Sigurd acquired a second facility in Hukou, Hsinchu County; its capacity was reportedly reserved by major international customers before operations began, per the same source.
Customers pre-booking a plant that has not yet started running is exactly the pattern seen with advanced packaging in prior shortage cycles.
One distinction needs to be stated plainly for anyone managing a risk register. This is a testing capacity constraint. It is not interchangeable with CoWoS or any other advanced-packaging shortage, because the reported allocation and price actions concern test services and test equipment. A buyer tracking packaging lead times on one line of a spreadsheet needs a second, separate line for test capacity. Treating the two as one metric hides the gap until a shipment misses.
Who Is Locking In Test Capacity, for How Long, and at What Price?
Most of Sigurd's customers have signed capacity-assurance agreements exceeding one year, according to the TrendForce report relayed by Futunn (2026). The practical consequence for anyone outside those agreements is that short-horizon demand competes for whatever remains after long-term contracts are served.
Which customers, and on which equipment
Some customers reserved capacity tied to specific equipment platforms rather than generic floor space, per Futunn (2026). That detail matters more than the headline. It means the constraint sits in process-specific test capability. A plant can have idle square metres and still have no open slot on the particular prober or burn-in platform that your device requires.
What "premium pricing" actually covers
Certain memory-chip customers agreed to pay more for guaranteed test access, and Sigurd confirmed price increases, according to Futunn (2026). The published material does not quantify the premium. A procurement team should therefore model exposure as "price increase confirmed, magnitude unknown" rather than plugging in a percentage borrowed from another node or another OSAT.
Why buyers accept the premium
Yield sensitivity explains the willingness to pay. The TrendForce report carried by Futunn (2026) cites an industry observation that a 1% yield difference in testing can create a significant cost difference on complex AI devices MLCC Prices September 2026: Standard Down, AI-Grade Up 105%. That figure is a reported observation, not a regulator-certified benchmark, but it describes the arithmetic correctly: on a high-value die that has already consumed scarce wafer and packaging capacity, unreliable or rushed test access risks more than a late delivery. It risks losing finished units.
What is documented and what is inferred
Explicitly named in Sigurd's 2026 investment plan, per Taiwan News (2026): AI processors, ASICs, HPC chips and optical-communications chips. Reported as price- or capacity-affected, per Futunn (2026): memory customers, which puts DRAM and HBM-adjacent supply inside the pressure zone, although no HBM-only figure exists. Not separately quantified anywhere in the reviewed reporting: GPU-specific and CPU-specific allocation volumes, and any distinct silicon-photonics shortage metric. Those families are exposed to the same platforms but should be logged as inferred exposure, not as confirmed data points.
What Does a Test Bottleneck Do to an OEM or EMS Production Line?
The direct consequence is that die or wafer supply you have already secured can still fail to arrive as a finished, tested component. Wafer inventory does not protect against a missing test slot, because the bottleneck has moved downstream of the point where most supply agreements stop.
Forward-booking also compresses your planning horizon from the outside. If OSAT customers are contracting test capacity 12 months or more ahead, per Futunn (2026), a procurement function working on quarterly visibility is structurally behind the market. The gap is not a forecasting error on your side; it is a change in how the capacity is sold.
ASIC programs are clearly exposed. According to Taiwan News (2026), ASIC testing is part of Sigurd's capex increase. If you're building a custom accelerator for stuff like industrial controllers, network appliances, or medical imaging systems, don't assume it follows the usual wafer or packaging timelines. The testing part has its own schedule.
Memory-dependent bills of materials NAND Flash Shortage 2026: Why Supply Stays Tight Until 2028 are facing cost pressures. When memory suppliers are paying extra for testing, those costs often show up somewhere down the line even if there isn't a confirmed industry-wide surcharge. Budget managers should expect tight budgets on DRAM and HBM items HBM4 Prices Up 121% in 2027: What OEM and EMS Buyers Must Plan For and should directly ask their suppliers whether testing capacity is locked in or just available when needed.
Ignoring this can lead to real issues. If a production line relies on an AI accelerator, a custom ASIC, or an HBM module without a secured testing slot, you can bet that line will stop, and no amount of wafer stock will save it. A halted line can create lost output that is difficult to recover within the planning period, depending on the program and the available capacity.
So, what do sourcing teams do when a bottleneck pops up?
First off, they might not even see it coming. When there's a hiccup in a step that wasn't monitored, teams often won't know which parts are stuck until a delivery gets missed. To fix this, they need to review the bill of materials and flag every component that relies on AI-related testing. Then, they should ask each supplier one clear question: Is your testing capacity locked in with a 12-month contract or is it based on demand?
Next, they need to break down availability into three parts: wafer allocation, packaging slot, and test slot. Each one is different - just because a supplier has one doesn't mean they have the others. If buyers lump them all into a single "lead time" category, they'll lose sight of what's causing delays.
Then, it's decision time. For long-term, stable projects, it's best to push for a testing capacity guarantee that covers testing, similar to what Sigurd's bigger clients are doing. Identify which programs are long enough to warrant forward test commitments Consumer MLCC Phase-Out: Why Your X5R Parts Face a 2029 Runway and which need a back-up plan with physical stock right now. For short runs or if there are gaps, it's probably better to find already-tested components that are sitting on the market.
Choosing the wrong option can cost a lot. Long-term agreements won't help if a line stops next week, and spot stock won't do much for a five-year project.
How can a specialist broker help when only tested stock works?
For short runs, a sourcing specialist comes in handy. They focus on finding already-tested inventory and not just factory capacity. This is where Origin Sourcing steps in. They look for components that OEMs, EMS providers, and distributors have as surplus stock, ensure everything checks out, and balance availability, traceability, delay, and risk for each purchase.
Here's a scenario from October 2026: An EMS provider making edge-computing boards for a European OEM has some wafer-backed custom ASICs, but the supplier's final test got pushed back by two quarters because their capacity is tied up elsewhere. The line is set to stop in seven weeks. The broker's job is clear: find finished, tested units of the same part number that another customer of the same supplier has, often from an earlier over-order. They'll check date codes, source documentation, and make sure everything meets the client's acceptance criteria before moving forward.
The broker's job isn't just about finding parts. If a source offers immediate stock but has no traceability, they'll pass on that in favor of a smaller quantity with full documentation. An untraceable AI device comes with reliability risks that production lines can't afford. They review each case with the client's needs for delay, budget, and risk tolerance clearly laid out, and management is directly involved rather than just handling requests through a system.
This method supports but doesn't replace long-term capacity agreements. It fills the gaps that forward contracts often can't cover in time.
What should be checked before the next forecast cycle?
Put in writing which critical components rely on AI testing platforms. Ask suppliers if test capacity is contracted or assumed and for how long. Add a line for test capacity to your risk register, separate from wafer and packaging. Identify which programs are long enough to warrant forward test commitments and which need a back-up plan with physical stock right now. Finally, set traceability standards for any parts sourced outside the main channels before the pressure of deadlines forces you to decide.
The Sigurd report is just one data point from an OSAT in Taiwan, reported by TrendForce and Taiwan News in 2026. It doesn't confirm a global test-price hike or a specific HBM shortage. What it shows is that test capacity is now being sold like advanced packaging: on a forward basis, under contract, and to whoever secures it first.
FAQ
Is test capacity really a separate issue from CoWoS packaging?
Absolutely. The allocation and pricing actions reported at Sigurd are all about test services and equipment, as per TrendForce via Futunn (2026). Test capacity and packaging capacity are dealt with through different contracts, so having a confirmed packaging slot doesn't guarantee you'll also have a test slot.
Which component families are most at risk in October 2026?
According to Sigurd's 2026 plan, AI processors, ASICs, HPC chips, and optical-communications chips are specifically named, as reported by Taiwan News (2026). Memory customers are reported to be paying premiums, based on Futunn (2026). GPU and CPU volumes aren't broken out separately, so treat them as inferred risks.
How big is the test-price increase?
No firm numbers have been released. Sigurd mentioned price hikes and some memory customers agreed to pay more, according to Futunn (2026), but specifics aren't available. You might think of it as a confirmed increase of an unknown size.
What can a buyer do if a line is about to stop in weeks, not months?
Forward capacity agreements won't arrive in time. The best option is to locate already-tested finished components that are available as excess stock, vet the source for traceability, and inspect them against your own acceptance criteria before making any commitments.
Does having wafer or die inventory protect against this bottleneck?
Not at all. If you have wafers without a test slot, you can't turn them into sellable components. The bottleneck happens after fabrication, which is why teams get caught off guard when their supply agreements only cover wafer or die allocation.